RT Journal Article
SR Electronic
T1 Advanced Restriction imaging and reconstruction Technology for Prostate MRI (ART-Pro): Study protocol for a multicenter, multinational trial evaluating biparametric MRI and advanced, quantitative diffusion MRI for detection of prostate cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.29.24311575
DO 10.1101/2024.08.29.24311575
A1 Baxter, Madison T
A1 Conlin, Christopher C
A1 Bagrodia, Aditya
A1 Barrett, Tristan
A1 Bartsch, Hauke
A1 Brau, Anja
A1 Cooperberg, Matthew
A1 Dale, Anders M
A1 Guidon, Arnaud
A1 Hahn, Michael E
A1 Harisinghani, Mukesh G
A1 Javier-DesLoges, Juan F
A1 Kamran (Capuano), Sophia
A1 Kane, Christopher J
A1 Kuperman, Joshua M
A1 Margolis, Daniel JA
A1 Murphy, Paul M
A1 Nakrour, Nabih
A1 Ohliger, Michael A
A1 Rakow-Penner, Rebecca
A1 Shabaik, Ahmed
A1 Simko, Jeffry P
A1 Tempany, Clare M.
A1 Wehrli, Natasha
A1 Woolen, Sean A
A1 Seibert, Tyler M
YR 2024
UL http://medrxiv.org/content/early/2024/08/29/2024.08.29.24311575.abstract
AB Background Multiparametric MRI (mpMRI) is strongly recommended by current clinical guidelines for improved detection of clinically significant prostate cancer (csPCa). However, major limitations of mpMRI are the need for intravenous (IV) contrast and dependence on reader expertise. Efforts to address these issues include use of biparametric MRI (bpMRI) and advanced, quantitative MRI techniques. One such advanced technique is the Restriction Spectrum Imaging restriction score (RSIrs), an imaging biomarker that has been shown to improve quantitative accuracy of patient- level csPCa detection.Purpose To evaluate whether IV contrast can be avoided in the setting of standardized, state-of-the-art image acquisition, with or without addition of RSIrs, and to evaluate characteristics of RSIrs as a stand-alone, quantitative biomarker.Design, setting, and participants ART-Pro is a multisite, multinational trial that will be conducted in two stages, evaluating bpMRI, mpMRI, and RSIrs on accuracy of expert (ART-Pro-1) and non-expert (ART-Pro-2) radiologists’ detection of csPCa. Additionally, RSIrs will be evaluated as a stand-alone, quantitative, objective biomarker (ART-Pro-1). This study will include a total of 500 patients referred for a multiparametric prostate MRI with a clinical suspicion of prostate cancer at any of the five participating sites (100 patients per site).Intervention In ART-Pro-1, patients receive standard of care mpMRI, with addition of the RSI sequence, and subsets of the patients’ images are read separately by two expert radiologists, one of whom is the standard of care radiologist (Reader 1). Three research reports are generated using: bpMRI only (Reader 1), mpMRI (Reader 1), and bpMRI + RSIrs (Reader 2). The clinical report is submitted by Reader 1. Patients’ future prostate cancer management will be recorded and used to evaluate the performance of the MRI techniques being tested.In ART-Pro-2, the dataset created in ART-Pro-1 will be retrospectively reviewed by radiologists of varying experience level (novice, basic, and expert). Radiologists will be assigned to read cases and record research reports while viewing subsets of either mpMRI only or RSIrs + mpMRI. Patient cases will be read by two readers from each experience level (6 reads total), and findings will be evaluated against the expertly created dataset from ART-Pro-1.Outcome measurements and statistical analysis The primary endpoint is to evaluate if bpMRI is non-inferior to mpMRI among expert radiologists (ART-Pro-1) and non-expert radiologists (ART-Pro-2) for detection of grade group (GG) ≥2 csPCa. We will conduct one-sided non-inferiority tests of correlated proportions (ART-Pro-1) and use McNemar’s test and AUC to test the null hypothesis of non-inferiority (ART-Pro-1 and ART-Pro-2).Conclusions Patient accrual at the first site (UC San Diego) began in December 2023. The expected trial timeline is three years to complete accrual with a six-month endpoint.Competing Interest StatementA.M.D. is a founder of and holds equity in CorTechs Labs, Inc, and serves on its scientific advisory board; he is also a member of the scientific advisory board of Human Longevity, Inc, and receives funding through research agreements with GE Healthcare. M.E.H. reports honoraria from Multimodal Imaging Services Corporation and research funding from GE Healthcare. R.R.P. has an equity interest in CorTechs Labs and CureMetrix, serves on the scientific advisory board of Imagine Scientific, and has received consulting fees from Bayer and research funding from GE Healthcare. A.G. and A.B. are employees of GE Healthcare. T.M.S. reports honoraria from CorTechs Labs, Varian Medical Systems, WebMD, GE Healthcare, Multimodal Imaging Services, and Janssen; he has an equity interest in CorTechs Labs, Inc, and serves on its scientific advisory board; he has also received in-kind research support from GE Healthcare via a research agreement with the University of California, San Diego. These companies might potentially benefit from the research results. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies.Clinical TrialNCT06579417Funding StatementThis study was funded by GE Healthcare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of University of California San Diego gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.